The Imaging Edge: Why You Should Consider MRI Biomarkers for Parkinson’s Disease Clinical Trials

Parkinson’s research continues to evolve, but relying on subjective clinical endpoints may be limiting your trial’s full potential. If you’re unsure about integrating imaging into your study design, The Imaging Edge offers the clarity you need.

This free eBook explores how MRI biomarkers, like neuromelanin-sensitive imaging and free water mapping, can provide objective, scalable insights into disease progression and treatment response.

Discover which MRI techniques are gaining traction, how they align with regulatory expectations, and why they’re becoming a strategic asset in modern PD trials. If you're rethinking your approach to endpoints, this guide will help you make an informed decision.